[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356348-105":59,"doc-detail-356348-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-profiling-directed-individualized-adjuvant-therapy-in-colorectal-cancer-bridging-consensus-guidelines-to-clinical-disparities","Molecular profiling-directed individualized adjuvant therapy in colorectal cancer: Bridging consensus guidelines to clinical disparities","","Colorectal cancer (CRC) adjuvant therapy is evolving from tumor-node-metastasis stage-based strategies toward molecular-profiling-guided precision medicine. This minireview, grounded in literature searches in PubMed and Web of Science (2010–2025), evaluates biomarkers such as mismatch repair status, RAS/RAF-related genomic alterations, consensus molecular subtypes, and circulating tumor DNA to refine risk stratification and treatment selection. It highlights persistent implementation gaps due to testing variability, limited evolving evidence (e.g., adjuvant immunotherapy for MMR-deficient/MSI-H), and health-economic barriers, and proposes integrated solutions across testing, decision-making, and monitoring.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-profiling-directed-individualized-adjuvant-therapy-in-colorectal-cancer-bridging-consensus-guidelines-to-clinical-disparities/356348/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-profiling-directed-individualized-adjuvant-therapy-in-colorectal-cancer-bridging-consensus-guidelines-to-clinical-disparities/356348.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarkers does the minireview emphasize for individualized CRC adjuvant therapy?","Question",{"text":112,"@type":113},"It emphasizes mismatch repair (MMR) status, RAS/rapidly accelerated fibrosarcoma mutations and other relevant genomic alterations, consensus molecular subtypes, and circulating tumor DNA (ctDNA). These biomarkers are described as tools to refine risk stratification and treatment choice.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do disparities persist between consensus guidelines and real-world implementation?",{"text":117,"@type":113},"Disparities stem from technical variability in biomarker testing, limited or still-evolving evidence for specific clinical scenarios, and health-economic barriers that affect access and uptake.",{"name":119,"@type":110,"acceptedAnswer":120},"What approaches are proposed to bridge gaps in CRC molecular profiling-based adjuvant care?",{"text":121,"@type":113},"The review proposes integrated solutions spanning technological innovation (including AI-integrated multiomics and ctDNA monitoring), optimized clinical pathways, and supportive health policies, enabled by multidisciplinary collaboration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356348,1790195546,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2026 February 7; 32(5): 115009  \nDOI: 10.3748/wjg.v32.i5.115009 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \nMINIREVIEWS  \nMolecular profiling-directed individualized adjuvant therapy in colorectal cancer: Bridging consensus guidelines to clinical disparities  \nXiao-Fei Cheng  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade A, Grade B  \nNovelty: Grade B, Grade B  \nCreativity or Innovation: Grade B, Grade C  \nScientific Significance: Grade B, Grade B  \nP-Reviewer: Smith J, PhD, South Africa; Wan HJ, Chief Nurse, Deputy Director, Professor, China  \nReceived: October 9, 2025  \nRevised: November 14, 2025  \nAccepted: December 19, 2025  \nPublished online: February 7, 2026  \nProcessing time: 115 Days and 8.7 Hours  \nXiao-Fei Cheng, Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China  \nCorresponding author: Xiao-Fei Cheng, MD, PhD, Associate Chief Physician, Department of Colorectal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No.  \n79 Qingchun Raod, Hangzhou 310003, Zhejiang Province, [China.](China. xfcheng@zju.edu.cn)[ xfcheng@zju.edu.cn](China. xfcheng@zju.edu.cn)  \nAbstract  \nColorectal cancer (CRC) adjuvant therapy is evolving from tumor-node-metastasis stage-based strategies toward molecular-profiling-guided precision medicine. This minireview, based on a comprehensive literature search in PubMed and Web of Science using keywords related to CRC biomarkers and adjuvant therapy (from 2010 to 2025), examines how key biomarkers, including mismatch repair (MMR) status, rat sarcoma viral oncogene homolog/rapidly accelerated fibrosarcoma mutations, consensus molecular subtypes, and circulating tumor DNA, refine risk stratification and treatment selection. Despite consensus guidelines advocating individualized therapy, significant disparities persist in real-world implementation due to technical variability in testing, limited or evolving evidence for specific scenarios (e.g., adjuvant immunotherapy for MMR-deficient/microsatellite instability-high patients, wherein phase 3 trials such as ATOMIC have yet to report mature overall survival data), and health economic barriers. The mini-review analyzes gaps across testing, decision-making, and dynamic monitoring phases, and proposes integrated solutions involving technological innovation (e.g., artificial intelligence-integrated multiomics, circulating tumor DNA monitoring), optimized clinical pathways, and supportive health policies. Bridging these gaps requires multidisciplinary collaboration to translate molecular insights into equitable, personalized adjuvant care for CRC patients.  \nKey Words: Colorectal cancer; Adjuvant therapy; Molecular subtyping; Consensus molecular subtypes; Circulating tumor DNA; Precision medicine  \n©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.  \n [https://dx.doi.org/10.3748/wjg.v32.i5.115009](https://dx.doi.org/10.3748/wjg.v32.i5.115009) 1 February 7, 2026  Volume 32  Issue 5   \nCheng XF. Molecular profiling in CRC adjuvant therapy  \nCore Tip: Molecular profiling, including mismatch repair deficiency/microsatellite instability, circulating tumor DNA (ctDNA), and consensus molecular subtypes, refines risk stratification and guides personalized adjuvant therapy in colorectal cancer. Persistent gaps between guidelines and practice stem from technical variability, limited evidence for novel strategies (e.g., ctDNA-guided escalation), and health economic disparities. Bridging these requires integrated artificial intelligencemultiomics decisi","cbCaig6l6svL3zoE","https://ap.wps.com/l/cbCaig6l6svL3zoE","pdf",2085786,15,"English","# Molecular profiling-directed individualized adjuvant therapy in colorectal cancer\n## Biomarkers for precision adjuvant treatment selection\n## Gaps between consensus guidelines and clinical disparities\n## Integrated solutions: testing, decision-making, and monitoring","[{\"question\":\"What biomarkers does the minireview emphasize for individualized CRC adjuvant therapy?\",\"answer\":\"It emphasizes mismatch repair (MMR) status, RAS/rapidly accelerated fibrosarcoma mutations and other relevant genomic alterations, consensus molecular subtypes, and circulating tumor DNA (ctDNA). These biomarkers are described as tools to refine risk stratification and treatment choice.\"},{\"question\":\"Why do disparities persist between consensus guidelines and real-world implementation?\",\"answer\":\"Disparities stem from technical variability in biomarker testing, limited or still-evolving evidence for specific clinical scenarios, and health-economic barriers that affect access and uptake.\"},{\"question\":\"What approaches are proposed to bridge gaps in CRC molecular profiling-based adjuvant care?\",\"answer\":\"The review proposes integrated solutions spanning technological innovation (including AI-integrated multiomics and ctDNA monitoring), optimized clinical pathways, and supportive health policies, enabled by multidisciplinary collaboration.\"}]","Molecular profiling-directed individualized adjuvant therapy in colorectal cancer: Bridging consensus guidelines to clinical disparities | PDF",1790124956,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16b57bfbeab2a95b2216a3824088b8c9.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/552b7ab25bda666021edd6092613ade0.webp",982,1389,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d49b51eed55c3847aafb4eadbaa9232f.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4f41a6d13b6d2719834e793f7414158.webp",980,1386]